Nine Masts Capital’s ProKidney PROK Stock Holding History

Nine Masts Capital’s Portfolio PROK Stock Details PROK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,244	Closed	-$22.9K	–	297
2025 Q4	$22.9K	Buy	+10,244	New	+$26.9K	﹤0.01%	97

Other funds holding PROK

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

AGP

Artia Global Partners Miami, Florida $499M AUM 186.05% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Nine Masts Capital's PROK Position: Q1 2026 in Review

Nine Masts Capital sold out of ProKidney (PROK) in Q1 2026, closing a stake of 10,244 shares — an estimated $22.9K sold.

Nine Masts Capital first reported a position in PROK in Q4 2025 and held it in 1 quarter. The position peaked at $22.9K in Q4 2025. 71 funds tracked by Wall St. Rank hold PROK as of Q1 2026.

Nine Masts Capital reported no remaining ProKidney position as of Q1 2026 after selling out during the quarter.
Nine Masts Capital sold 10,244 ProKidney shares in Q1 2026, an estimated $22.9K.
Nine Masts Capital first reported a position in ProKidney in Q4 2025 and held it in 1 quarter.
Nine Masts Capital's ProKidney position peaked at $22.9K in Q4 2025.
71 funds tracked by Wall St. Rank held ProKidney as of Q1 2026.

Based on Nine Masts Capital's 13F filing for Q1 2026, filed 13 May 2026.